Latest Breaking News On - Tyrosine kinase inhibitor evobrutinib - Page 1 : comparemela.com

Evobrutinib continues to be well tolerated among people with relapsing forms of multiple sclerosis and relapse rates continue to be low.

United statesSan diegoJan klattMerck kgaMerck kgaaAmericas committee for treatmentResearch in multiple sclerosisAmericas committeeMultiple sclerosisTyrosine kinase inhibitor evobrutinibRelapsing multiple sclerosis overLabel extensionNorth america